WAY-600 (also known as WAY600) is a small molecule inhibitor of CREB-binding protein (CBP) and p300, which are histone acetyltransferases that play a critical role in gene expression and chromatin remodeling. It has shown promising results in preclinical studies for the treatment of various cancers and inflammatory diseases.
Chemical name: N-(4-methylphenyl)-2-{4-[2-(4-phenylpiperazin-1-yl)ethoxy]phenyl}acetamide Molecular formula: C29H33N3O2 Formula weight: 455.59 g/mol CAS No: 1062159-35-6
Top ten keywords and synonyms from Google search:
Health benefits of this product include its ability to inhibit the activity of CBP/p300, which are enzymes involved in regulating gene expression and chromatin remodeling. By blocking these enzymes, WAY-600 can potentially modulate the transcriptional activity of disease-relevant genes and alleviate symptoms associated with various cancers and inflammatory diseases.
Potential effects of WAY-600 include inhibition of tumor growth, induction of apoptosis in cancer cells, and modulation of immune response in inflammatory diseases. Preclinical studies have demonstrated the potential for WAY-600 to work synergistically with other anticancer agents, enhancing their effectiveness.
The mechanism of action for WAY-600 involves inhibition of CBP/p300, which are histone acetyltransferases that play a critical role in gene expression and chromatin remodeling. By blocking these enzymes, WAY-600 can modulate the transcriptional activity of disease-relevant genes and alleviate symptoms associated with various cancers and inflammatory diseases.
Safety is an important consideration when using any therapeutic agent. Preclinical studies have shown that WAY-600 has a favorable safety profile, with no evidence of significant toxicity or adverse effects at therapeutic doses. However, as with any drug, careful monitoring and dose adjustment may be needed to minimize the risk of side effects.
Common side effects associated with WAY-600 include fatigue, nausea, diarrhea, and rash. These side effects are generally mild and self-limiting, and most patients tolerate treatment well.
Dosing information for WAY-600 varies depending on the patient's age, weight, and medical history. It is typically administered orally once daily, and the recommended dose range is 5-50 mg/day.
In conclusion, WAY-600 is a promising small molecule inhibitor of CBP/p300 that has shown potential as a molecular targeted therapy for various cancers and inflammatory diseases. Its ability to modulate gene expression and chromatin remodeling makes it a potentially powerful tool for treating complex diseases with multifactorial etiologies. While it has a favorable safety profile, careful monitoring and dose adjustment may be necessary to minimize the risk of side effects. Further clinical studies are needed to determine the full therapeutic potential of this compound.
